TAVR vs. the Least Invasive Surgically Implanted Valve

Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional bioprostheses, which require several stitches. These valves, which shorten surgical times, could compete with transcatheter-implanted valves (transcatheter aortic valve replacement, TAVR).

TAVI vs la válvula quirúrgica menos invasiva

The German Aortic Valve Registry analyzed 16,473 patients who underwent surgical aortic valve replacement with either a current-generation rapid-release valve or current-generation TAVR between 2011 and 2017.

Results from both procedures and devices were compared after matching patients 1:1 using propensity score.

TAVR patients were older and had higher surgical risk scores than those who underwent surgery.

Patients who underwent surgical valve replacement with rapid-release valves suffered from more disabling stroke (1.7% vs. 1.1%; p = 0.03) and needed more transfusions (8.5% vs. 1.4%; p < 0.001) and dialysis (1.9% vs. 1.2%; p = 0.01). Besides that, they had lower pacemaker implantation rates than their TAVR counterparts (8.4% vs. 14.9%; p < 0.001). 

In-hospital mortality was similar (1.6% vs. 1.8%; p = 0.62) when analyzing raw data, but after propensity score matching, a significant advantage in favor of TAVR was found (1.7% vs. 0.6%; p = 0.003).


Read also: The Best Anticoagulant Agent for AF After TAVR.


Balloon-expandable rapid-release valves had lower residual gradients than balloon-expandable TAVR. The opposite was observed with self-expanding valves, with which rapid-release valves had higher gradients.

Conclusion

This large registry of patients with aortic stenosis showed that TAVR presents an advantage in terms of in-hospital mortality compared with surgery using rapid-release valves. Rapid-release surgically implanted valves were better than percutaneous valves only in terms of pacemaker implantation.

Hemodynamic results varied according to the release mechanism of the device.

j-jcin-2020.09.018

Título original: Transcatheter Versus Rapid-Deployment Aortic Valve Replacement. A Propensity-Matched Analysis From the German Aortic Valve Registry.

Referencia: Mohamed Abdel-Wahab et al. J Am Coll Cardiol Intv 2020;13:2642–54. https://doi.org/10.1016/j.jcin.2020.09.018.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...